{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-215909","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.521259+00:00","generated_at":"2026-05-31T05:51:33.320690+00:00","sec_items":["1.03","3.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Eiger BioPharmaceuticals Chapter 11 liquidation plan confirmed; all equity cancelled","bullets":["Bankruptcy Court entered confirmation order on Sept 5, 2024, for Fifth Amended Joint Plan of Liquidation.","All 1,480,797 shares of common stock to be cancelled on effective date; no recovery for equity holders.","Assets sold: Zokinvy to Sentynl, Avexitide to Amylyx, Lonafarnib/Lambda to Eiger InnoTherapeutics.","As of July 31, 2024, Debtors reported ~$65.6M assets and ~$40M liabilities (unaudited).","Liquidating Trustee and Plan Administrator to wind down operations and administer trust assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-215909","json":"https://secwatch.observer/filing/0001193125-24-215909.json","markdown":"https://secwatch.observer/filing/0001193125-24-215909.md","text":"https://secwatch.observer/filing/0001193125-24-215909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/0001193125-24-215909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/d887098d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:51:33.320690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0eed5f7dd725ac84b897aafc6189b33a2fb2d5d","claim":"Eiger BioPharmaceuticals, Inc. entered chapter 11 in United States Bankruptcy Court for the Northern District of Texas (petition 2024-04-01).","evidence_excerpt":"As previously disclosed, on April 1, 2024, Eiger BioPharmaceuticals, Inc. (the “ Company ”) and its direct subsidiaries (together the “ Debtors ”) filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the Northern District of Texas (the “ Bankruptcy Court ”) under the caption In re Eiger BioPharmaceuticals, Inc., et al , Case No. 24-80040 (the “ Chapter 11 Cases ”).","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524215909/0001193125-24-215909-index.htm","confidence":0.99,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the Northern District of Texas"},{"label":"Petition","value":"2024-04-01"}],"fact_type":"distress_event"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}